{"id":218554,"date":"2025-07-23T12:04:25","date_gmt":"2025-07-23T17:04:25","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2025\/07\/unm-researchers-receive-funding-to-launch-clinical-trial-of-a-new-alzheimers-vaccine"},"modified":"2025-07-23T12:04:25","modified_gmt":"2025-07-23T17:04:25","slug":"unm-researchers-receive-funding-to-launch-clinical-trial-of-a-new-alzheimers-vaccine","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2025\/07\/unm-researchers-receive-funding-to-launch-clinical-trial-of-a-new-alzheimers-vaccine","title":{"rendered":"UNM Researchers Receive Funding to Launch Clinical Trial of a New Alzheimer\u2019s Vaccine"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/unm-researchers-receive-funding-to-launch-clinical-trial-of-a-new-alzheimers-vaccine.jpg\"><\/a><\/p>\n<p>University of New Mexico researchers have received funding to launch an early-stage clinical trial of a vaccine engineered to clear pathological tau protein from the brains of patients suffering from Alzheimer\u2019s dementia.<\/p>\n<p>The Phase 1a\/1b trial, supported in part by a $1 million grant from the Alzheimer\u2019s Association\u2019s Part the Cloud initiative, will test the novel vaccine, which was developed by UNM School of Medicine scientists, said Kiran Bhaskar, PhD, professor in the Departments of Molecular Genetics &amp; Microbiology and Neurology.<\/p>\n<p>\u201cThe primary endpoint of this study is safety and tolerability,\u201d he said. \u201cCan these subjects take these vaccinations without any anticipated side effects or adverse events? The second endpoint is the immunogenicity \u2013 can they make antibodies to tau?\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"<p>University of New Mexico researchers have received funding to launch an early-stage clinical trial of a vaccine engineered to clear pathological tau protein from the brains of patients suffering from Alzheimer\u2019s dementia. The Phase 1a\/1b trial, supported in part by a $1 million grant from the Alzheimer\u2019s Association\u2019s Part the Cloud initiative, will test the [\u2026]<\/p>\n","protected":false},"author":534,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1902,11,412,47],"tags":[],"class_list":["post-218554","post","type-post","status-publish","format-standard","hentry","category-bioengineering","category-biotech-medical","category-genetics","category-neuroscience"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/218554","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/534"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=218554"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/218554\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=218554"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=218554"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=218554"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}